Provided by Tiger Trade Technology Pte. Ltd.

XILIO THERAPEUTICS, INC.

0.5962
+0.061211.44%
Post-market: 0.5798-0.0164-2.75%19:59 EST
Volume:1.78M
Turnover:993.84K
Market Cap:40.27M
PE:-0.98
High:0.6058
Open:0.5600
Low:0.5201
Close:0.5350
52wk High:1.70
52wk Low:0.5030
Shares:67.54M
Float Shares:36.44M
Volume Ratio:3.95
T/O Rate:4.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6100
EPS(LYR):-1.0884
ROE:-908.28%
ROA:-26.26%
PB:-4.97
PE(LYR):-0.55

Loading ...

Xilio Therapeutics Prices Pre-Funded Warrant Offering Financing

TIPRANKS
·
9 hours ago

BRIEF-Xilio Therapeutics Announces Pricing Of Underwritten Offering

Reuters
·
Yesterday

Xilio Therapeutics Prices $40 Million Pre-Funded Warrant Offering

Reuters
·
Yesterday

Xilio Therapeutics Inc - Gross Proceeds From Offering Are Expected to Be Approximately $40.0 Mln

THOMSON REUTERS
·
Yesterday

Xilio Therapeutics Announces Pricing of Underwritten Offering

THOMSON REUTERS
·
Yesterday

Xilio Therapeutics Inc. Announces Date for Special Stockholders Meeting

Reuters
·
Jan 17

Xilio Therapeutics Announces Leadership Transition and Pipeline Updates

TIPRANKS
·
Jan 08

BRIEF-Xilio Therapeutics Inc Appoints Sara Bonstein As Chair Of Board

Reuters
·
Jan 08

Xilio Therapeutics Inc - Appoints Sara Bonstein as Chair of Board

THOMSON REUTERS
·
Jan 08

Xilio Therapeutics Raises $35.8 Million Through Series B Warrant Exercises

Reuters
·
Jan 08

Press Release: Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Dow Jones
·
Jan 08

Xilio Therapeutics SVP Kevin M. Brennan Reports Sale of Common Shares

Reuters
·
Jan 06

Xilio Therapeutics Raises $35.8 Million From Series B Warrant Exercises

Reuters
·
Jan 05

Xilio Therapeutics Inc. held special shareholder meeting

Reuters
·
Nov 26, 2025

Xilio Therapeutics Q3 Net Income USD -16.287 Million

Reuters
·
Nov 20, 2025

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annua

Reuters
·
Nov 20, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Applied Therapeutics (APLT) and Xilio Therapeutics (XLO)

TIPRANKS
·
Nov 14, 2025

Xilio Therapeutics' Q3 collaboration revenue rises

Reuters
·
Nov 13, 2025

BRIEF-Xilio Therapeutics Q3 Net Income USD -16.287 Million

Reuters
·
Nov 13, 2025

Xilio Therapeutics Inc - Anticipates Cash Runway Into Q1 2027

THOMSON REUTERS
·
Nov 13, 2025